Akums Drugs
Akums Drugs Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force. CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.
From Akums Drugs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force.
- CDMO segment showed healthy volume growth of over 18% year-on-year; Q2 volume growth also looks strong at high teens, with positive momentum expected to continue.
- Overall volume growth in the industry is expected to sustain, with the company positioned to outperform market growth.
- New manufacturing capacities (e.g., in oral tablets and a new facility in Baddi) coming online by year-end are expected to support volume growth.
- International branded formulations and Zambia business are forecasted to contribute revenue growth, with Zambia expected to recognize revenues in H2 FY27 and European business operations kicking in next year.
- The API business aims to become monthly EBITDA positive by Feb-Mar FY27, turning profitable next year, with single-digit growth expected by FY28.
Profitability & Margins
See what Akums Drugs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
- The capex for this new facility is still under discussion and will be updated once finalized.
- The company has INR1,600 crores of cash on the balance sheet, mostly parked in fixed deposits with nationalized banks, with no debt.
- Akums is open to acquisitions that are value-accretive and strategically rational to the group, indicating potential future inorganic investments.
- Management emphasizes cautious capital allocation for acquisitions, focusing on business synergies and profitability enhancement.
- Recent acquisition of Oriflame India's manufacturing business expanded capacities in skincare cosmetics and wellness products, aligning with the strategy of tapping niche formulations.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Akums Drugs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Akums Drugs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Akums Drugs & Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Akums Drugs Q1 FY27 results?
The company expects double-digit volume growth for the domestic branded formulation (Akumentis) business in the coming quarters and years, driven by new product launches and expansion into adjacent geographies with increased field force. CDMO segment expects continued high teens volume growth; Q2 looks strong with steady API prices trending upwards.
What is Akums Drugs share price analysis?
Akums Drugs currently shows a below-average growth signal. The stock trades at a P/E of 38.7 with a market cap of ₹11,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Akums Drugs planning capital expenditure?
Akums is in the process of setting up one more oral manufacturing facility in Baddi, expected to go live by the end of FY27, which will significantly boost oral manufacturing capabilities.
Keep Akums Drugs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.